Results 31 to 40 of about 70,105 (273)
Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
Genome Medicine, 2018 Editorial summary Inhibitors of poly(ADP-ribose) polymerase (PARPi) have entered the clinic for the treatment of patients with cancers that lack homology-directed DNA repair, but drug resistance remains a clinical hurdle.
Paola Francica, Sven Rottenberg
doaj +1 more source
Inhibition of efflux transporters by poly ADP‐ribose polymerase inhibitors
Basic & Clinical Pharmacology & Toxicology, 2023 AbstractPoly ADP‐ribose polymerase (PARP) inhibitors have been approved for the treatment of various cancers. They share a similar mechanism of action but have differences in pharmacokinetic characteristics and potential for drug–drug interactions (DDI).
Feng Deng +3 more
openaire +3 more sources
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
Women's Health, 2018 There is considerable interest and enthusiasm within the clinical gynecologic oncology community regarding the potential for poly (ADP-ribose) polymerase inhibitors to play a critically relevant role in the management of epithelial ovarian cancer and ...
Maurie Markman
doaj +1 more source
PARP inhibition: a promising therapeutic target in ovarian cancer [PDF]
, 2015 Ovarian cancer is burdened by the highest mortality rate among gynecological cancers. Gold standard is represented by the association of platinum-taxane -based chemotherapy and radical surgery.
Abdul Halim, T +14 more
core +1 more source
Niraparib in ovarian cancer. results to date and clinical potential [PDF]
, 2017 Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA1 and 2, two genes involved in the mechanisms of reparation of DNA damage, are showed to be related with the incidence of breast and ovarian cancer, both ...
Benedetti Panici, Pierluigi +5 more
core +1 more source
Evaluation of melanin-targeted radiotherapy in combination with radiosensitizing drugs for the treatment of melanoma [PDF]
, 2014 The incidence of malignant melanoma is rising faster than that of any other cancer in the United States. An [131I]-labeled benzamide - [131I]MIP-1145 - selectively targets melanin, reduces melanoma tumor burden and increases survival in preclinical ...
Babich, John +5 more
core +1 more source
Targeting DNA damage response deficiency in the treatment of breast cancer [PDF]
Zhongguo aizheng zazhi, 2022 DNA damage response (DDR) deficiency has been one of the emerging targets in treating breast cancer in recent years. The DDR pathway is essential for the identification, signal transduction and repair of DNA damage.
JIN Yizi, LIN Mingxi, ZHANG Jian
doaj +1 more source
Poly(ADP-ribose) polymerase inhibitors as cancer therapy
Frontiers in Bioscience, 2013 Poly(ADP-ribose) polymerase (PARP) inhibitors are pharmacologic agents which primarily inhibit the PARP-1 and PARP-2 enzymes within the cell. Inhibition of PARP results in failure of base-excision repair (BER) to correct single-stranded breaks in DNA.
John F, Hilton +3 more
openaire +2 more sources
Pan-cancer landscape of homologous recombination deficiency
Nature Communications, 2020 Cancers deficient in homologous recombination can benefit from treatment with poly ADP-ribose polymerase (PARP) inhibitors. Here, the authors generated a classifier that can predict homologous recombination deficiency from genomic data and suggest ...
Luan Nguyen +3 more
doaj +1 more source
PARP-1 regulates DNA repair factor availability. [PDF]
, 2018 PARP-1 holds major functions on chromatin, DNA damage repair and transcriptional regulation, both of which are relevant in the context of cancer. Here, unbiased transcriptional profiling revealed the downstream transcriptional profile of PARP-1 enzymatic
Birbe, Ruth +31 more
core +2 more sources